Dow Jones
37.948,98 -437,11 (-1,14%) Nasdaq
15.793,63 -189,45 (-1,19%) Nikkei 225
38.405,66 +470,90 (+1,24%) EUR/USD
1,0679 -0,0046 (-0,43%) Bitcoin EUR
56.328,34 -2.413,64 (-4,11%) CMC Crypto 200
1.277,56 -61,51 (-4,59%)
Hyloris Pharmaceuticals SA (0AB6.L)
| Chiusura precedente | 12,78 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 258 |
| Capitalizzazione | 3,31M |
| Beta (5 anni mensile) | 0,58 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,45 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireHyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
Total revenue and other income nearly doubled (€2,4 million, +95%)R&D progress across the board, including initiation of the 4-arm Phase 2 clinical trial for AlenuraTM, targeting IC/BPS, a condition affecting at least 6 million U.S. patientsPDUFA goal date for Maxigesic® IV set for 17 October 2023 by the U.S. FDA1Evaluating external product candidates & advancing internal projects to reach 30 key assets before 2025Multiple NDA2 submissions expected within the next 18 monthsAnalyzing different go
GlobeNewswireHyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)
Potential first-line treatment for interstitial cystitis/bladder pain syndrome (IC/BPS)Global opportunity with a patient population of at least 6 million in the U.S. alone1 Liège, Belgium – 22 June 2023 – 7AM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of Al
- GlobeNewswire
Hyloris shareholders approve all resolutions at the Annual General Meeting
56,22% of shares represented physically, virtually or by proxy voteAll documents related to the 2023 AGM are available on the Hyloris website Regulated Information – Inside Information - Liège, Belgium – 13 June 2023 – 6PM CET - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces the approval of all resolutions proposed at its Annual General Meeting (AGM) held at i
